Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

• DOI: 10.1200/jco.2023.41.6_suppl.724
• Publication Date: 2023-03-14T15:22:32Z
• Authors: Lucia Carril-Ajuria; Marie Naigeon; Cécile Dalban; Aude Desnoyer; Nathalie Rioux-Le...; Catherine Sautès-...; Maxime Meylan; Yann-Alexandre Vano; Benoit Beusenlick; Salem Chouaib; Caroline de Oliveira; Florence Tantot; Ronan Flippot; Bernard Escudier; Laurence Albiges; Nathalie Chaput
• Keywords: [SDV]Life Sciences [q-bio]; 3. Good health

724 Background: The NIVOREN GETUG-AFU 26 study launched a translational research program to quantify baseline circulating soluble factors levels and correlate them with outcomes irAEs in mRCC pts treated nivolumab. We previously identified (training-set = 80 pts, validation-set= 233 pts) several associated overall survival (IL-6, IL-8, VEGF, BAFF, CXCL13) (Carril-Ajuria et al. ASCO. 2022). Our aim was evaluate the association between of presence all grade severe irAEs. Methods: 720 patients nivolumab within available safety data were included study. seven different (VEGF, VCAM-1, IL-6, IL-7, development evaluated those who had undergone quantification program. other systemic inflammatory markers (the lung immune prognostic index (LIPI), LDH derived neutrophil lymphocyte ratio (dNLR)) also evaluated. Results: Out 456 (63%) 143 (20%) presented respectively. Soluble at for 353 pts. Baseline characteristics similar trial population. Lower IL-6 (cut-off: 8.7 pg/ml) significantly higher risk (p=0.025). dNLR (<3, p=0.003) good LIPI score (p=0.014) AEs. No significant associations found solubles factors/systemic Conclusions: Using cut-off values identified, we observed that lower an increased Good failed demonstrate